Syndax Pharmaceuticals, Inc. (SNDX) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
41/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 7 wins, 5 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseSNDX / S&P -6.42% / 15.20% |
WinSNDX / S&P 222.65% / 15.00% |
LoseSNDX / S&P -35.31% / 50.40% |
| 2026-Q12/3 |
WinSNDX / S&P 11.19% / -4.33% |
WinSNDX / S&P 397.28% / 11.30% |
LoseSNDX / S&P -27.53% / 27.70% |
| 2025-Q42/3 |
WinSNDX / S&P 36.56% / 2.65% |
WinSNDX / S&P 628.88% / 9.00% |
LoseSNDX / S&P -11.56% / 13.40% |
| 2025-Q32/3 |
WinSNDX / S&P 64.28% / 8.12% |
WinSNDX / S&P 597.19% / 4.61% |
LoseSNDX / S&P -1.10% / 13.45% |
| 2025-Q22/3 |
LoseSNDX / S&P -23.77% / 10.94% |
WinSNDX / S&P 2133.71% / 4.83% |
WinSNDX / S&P 14.45% / 10.63% |
| 2025-Q11/3 |
LoseSNDX / S&P -7.07% / -4.27% |
LoseSNDX / S&P SNDX unavailable / 4.98% |
WinSNDX / S&P 19.20% / 10.57% |
| 2024-Q41/3 |
LoseSNDX / S&P -31.32% / 2.41% |
LoseSNDX / S&P SNDX unavailable / 5.25% |
WinSNDX / S&P 25.25% / 6.15% |
| 2024-Q31/3 |
LoseSNDX / S&P -6.23% / 5.89% |
LoseSNDX / S&P SNDX unavailable / 5.89% |
WinSNDX / S&P 41.09% / 6.11% |
| 2024-Q21/3 |
LoseSNDX / S&P -13.74% / 4.28% |
LoseSNDX / S&P SNDX unavailable / 5.38% |
WinSNDX / S&P 39.51% / 5.12% |
| 2024-Q11/3 |
LoseSNDX / S&P 10.13% / 10.56% |
LoseSNDX / S&P SNDX unavailable / 5.71% |
WinSNDX / S&P 34.02% / 5.59% |
| 2023-Q42/3 |
WinSNDX / S&P 48.83% / 11.69% |
LoseSNDX / S&P SNDX unavailable / 6.81% |
WinSNDX / S&P 21.22% / 7.78% |
| 2023-Q30/3 |
LoseSNDX / S&P -30.63% / -3.27% |
LoseSNDX / S&P SNDX unavailable / 7.52% |
LoseSNDX / S&P -25900.00% / -5.03% |
| 2023-Q20/3 |
LoseSNDX / S&P -0.90% / 8.74% |
LoseSNDX / S&P SNDX unavailable / 9.50% |
LoseSNDX / S&P -1378.95% / -8.57% |
| 2023-Q10/3 |
LoseSNDX / S&P -17.01% / 7.50% |
LoseSNDX / S&P SNDX unavailable / 10.77% |
LoseSNDX / S&P -751.35% / -15.69% |
| 2022-Q40/3 |
LoseSNDX / S&P 5.91% / 7.56% |
LoseSNDX / S&P SNDX unavailable / 11.88% |
LoseSNDX / S&P SNDX unavailable / -17.99% |
| 2022-Q31/3 |
WinSNDX / S&P 24.90% / -4.88% |
LoseSNDX / S&P SNDX unavailable / 13.47% |
LoseSNDX / S&P SNDX unavailable / -1.41% |
| 2022-Q21/3 |
WinSNDX / S&P 10.70% / -16.10% |
LoseSNDX / S&P SNDX unavailable / 13.71% |
LoseSNDX / S&P SNDX unavailable / 11.04% |
| 2022-Q10/3 |
LoseSNDX / S&P -20.60% / -4.60% |
LoseSNDX / S&P SNDX unavailable / 15.97% |
LoseSNDX / S&P SNDX unavailable / 42.23% |
| 2021-Q42/3 |
WinSNDX / S&P 14.55% / 11.03% |
WinSNDX / S&P 9115.63% / 15.00% |
LoseSNDX / S&P SNDX unavailable / 96.40% |
| 2021-Q32/3 |
WinSNDX / S&P 11.30% / 0.58% |
WinSNDX / S&P 791.29% / 10.77% |
LoseSNDX / S&P SNDX unavailable / 69.42% |
| 2021-Q20/3 |
LoseSNDX / S&P -23.21% / 8.55% |
LoseSNDX / S&P 0.00% / 6.58% |
LoseSNDX / S&P SNDX unavailable / 51.81% |
| 2021-Q11/3 |
LoseSNDX / S&P 0.54% / 6.17% |
WinSNDX / S&P 0.00% / -1.06% |
LoseSNDX / S&P SNDX unavailable / 7.39% |
| 2020-Q42/3 |
WinSNDX / S&P 50.68% / 12.15% |
WinSNDX / S&P 0.00% / -3.72% |
LoseSNDX / S&P SNDX unavailable / -33.42% |
| 2020-Q31/3 |
LoseSNDX / S&P -0.40% / 8.93% |
WinSNDX / S&P 0.00% / -2.04% |
LoseSNDX / S&P SNDX unavailable / -27.10% |
| 2020-Q22/3 |
WinSNDX / S&P 35.10% / 20.54% |
WinSNDX / S&P 0.00% / -0.46% |
LoseSNDX / S&P SNDX unavailable / -27.11% |
| 2020-Q11/3 |
WinSNDX / S&P 24.94% / -19.60% |
LoseSNDX / S&P 0.00% / 3.47% |
LoseSNDX / S&P SNDX unavailable / -14.75% |
| 2019-Q41/3 |
WinSNDX / S&P 17.54% / 9.07% |
LoseSNDX / S&P 0.00% / 5.36% |
LoseSNDX / S&P SNDX unavailable / 2.99% |
| 2019-Q30/3 |
LoseSNDX / S&P -19.76% / 1.70% |
LoseSNDX / S&P -34.94% / 5.02% |
LoseSNDX / S&P SNDX unavailable / 0.21% |
| 2019-Q21/3 |
WinSNDX / S&P 77.33% / 4.30% |
LoseSNDX / S&P -32.80% / 6.64% |
LoseSNDX / S&P SNDX unavailable / 8.65% |
| 2019-Q11/3 |
WinSNDX / S&P 17.98% / 13.65% |
LoseSNDX / S&P -30.52% / 8.12% |
LoseSNDX / S&P SNDX unavailable / 14.29% |
| 2018-Q40/3 |
LoseSNDX / S&P -44.93% / -13.52% |
LoseSNDX / S&P -28.08% / 9.05% |
LoseSNDX / S&P SNDX unavailable / 18.23% |
| 2018-Q32/3 |
WinSNDX / S&P 15.10% / 7.71% |
WinSNDX / S&P 90.98% / 10.21% |
LoseSNDX / S&P SNDX unavailable / 19.06% |
| 2018-Q21/3 |
LoseSNDX / S&P -50.67% / 3.43% |
WinSNDX / S&P 84.92% / 9.03% |
LoseSNDX / S&P SNDX unavailable / 14.46% |
| 2018-Q12/3 |
WinSNDX / S&P 62.44% / -0.76% |
WinSNDX / S&P 78.85% / 7.68% |
LoseSNDX / S&P SNDX unavailable / 12.46% |
| 2017-Q41/3 |
LoseSNDX / S&P -25.13% / 6.64% |
WinSNDX / S&P 72.79% / 7.03% |
LoseSNDX / S&P SNDX unavailable / 13.82% |
| 2017-Q30/3 |
LoseSNDX / S&P -16.25% / 4.48% |
LoseSNDX / S&P 0.00% / 5.68% |
LoseSNDX / S&P SNDX unavailable / 17.57% |
| 2017-Q20/3 |
LoseSNDX / S&P 1.82% / 3.09% |
LoseSNDX / S&P 0.00% / 4.83% |
LoseSNDX / S&P SNDX unavailable / 17.74% |
| 2017-Q12/3 |
WinSNDX / S&P 91.35% / 6.07% |
WinSNDX / S&P 30.90% / 3.67% |
LoseSNDX / S&P SNDX unavailable / 13.32% |
| 2016-Q40/3 |
LoseSNDX / S&P -52.70% / 3.82% |
LoseSNDX / S&P SNDX unavailable / 2.09% |
LoseSNDX / S&P SNDX unavailable / 7.05% |
| 2016-Q31/3 |
WinSNDX / S&P 53.91% / 3.85% |
LoseSNDX / S&P SNDX unavailable / 0.20% |
LoseSNDX / S&P SNDX unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | SNDX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 23.45% | 20.78% |
| Annualized return | 23.45% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | SNDX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 11.57% | 83.14% |
| Annualized return | 2.21% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | SNDX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 44.62% | 319.30% |
| Annualized return | 3.76% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |